Romosozumab May Not Increase Cardiovascular Risk After All ...Middle East

Medscape - News
Alarm bells went off at the FDA because during year 1 of the ARCH trial, the incidence of adjudicated major adverse cardiovascular events was 2.5% in the romosozumab arm, compared with 1.9% with alendronate. Medscape Medical News

Hence then, the article about romosozumab may not increase cardiovascular risk after all was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Romosozumab May Not Increase Cardiovascular Risk After All )

Apple Storegoogle play

Last updated :

Also on site :